Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs5.32 M7.25 M6.48 M6.07 M7.44 M4.29 M—Recherche et développement17.29 M21.13 M20.79 M20.78 M16.65 M7.99 M—Résultat d'exploitation24.81 M30.95 M26.94 M26.51 M22.21 M14.03 M—Total des produits hors exploitation———————Charges d'intérêts, nettes des intérêts capitalisés———————Résultat hors exploitation, hors charges d'intérêts———————Revenus/dépenses exceptionnels———————Résultat avant impôts26.17 M30.43 M29.75 M25.99 M18.05 M13.5 M—Part des actionnaires dans le résultat———————Impôts32 K13 K90 K33 K9 0001 000—Intérêts ne donnant pas le contrôle / intérêts minoritaires2.83 M2.65 M3.21 M2.08 M1.57 M658 K—Autres produits/charges après impôts———————Résultat net avant activités abandonnées26.21 M30.45 M29.84 M25.95 M18.05 M2.15 M—Activités abandonnées—————5.67 M—Résultat net26.21 M30.45 M29.84 M25.95 M18.05 M7.83 M—Ajustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires———————Bénéfice par action de base (BPA de base)———————Bénéfice par action dilué (BPA dilué)———————Nombre moyen d'actions de base en circulation———————Nombre d'actions en circulation après dilution———————EBITDA-24.24 M————-9.42 M—EBIT-24.24 M-30.19 M-26.03 M-24.82 M-19.53 M-9.94 M—Coût des ventes574 K767 K909 K1.69 M2.68 M4.09 M—Autres coûts des ventes———————Amortissements (flux de trésorerie)0————522 K—
Evogene Ltd. - Ordinary Shares
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture.